Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of CC-292 SDD in Healthy Volunteers
NCT02433457Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- May 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of spebrutinib in rheumatoid arthritis (RA), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and 2 more (7 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum Plasma Concentration at 48 hours, Area Under the Curve from time zero to last measurable concentration at 48 hours and 6 more. Started May 2014; status: completed.
02
Drugs
spebrutinib
03
Conditions
rheumatoid arthritis (RA)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)B-cell non-Hodgkin lymphomaWaldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT02433457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02433457.